Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193)

Journal of Clinical Oncology

Volumn 21, Issue 4, 2003, Pages 588-592

  Sledge, George W ^a   Neuberg, Donna ^a   Bernardo, Patricia ^a   Ingle, James N ^a   Martino, Silvana ^a   Rowinsky, Eric K ^a   Wood, William C ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; METASTASIS; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; SURVIVAL RATE;

EID: 0037441856     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.013     Document Type: Article

References (21)

1. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
2. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
3. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995
4. Schabel FM: Synergism and Antagonism Among Antitumor Agents. The Pharmacologic Basis of Cancer Chemotherapy. Baltimore, Williams and Wilkins, 1975, pp 595-623
5. Frei E III: Combination cancer therapy: Presidential address. Cancer Res 32:2593-2607, 1972
6. Friedland M: Combination chemotherapy, in Perry M (ed): The Chemotherapy Source Book (ed 2). Baltimore, Williams & Wilkins, 1997, pp 101-107
7. Greenspan E, Fieber M, Lesnick G, et al: Response of advanced breast carcinoma to the combination of the antimetabolite methotrexate and the alkylating agent thio-TEPA. J Mt Sinai Hosp 30:246-267, 1963
8. Canellos G, Pocock S, Taylor SI, et al: Combination chemotherapy for metastatic breast carcinoma. Cancer 38:1882-1886, 1976
9. Rubens R, Knight R, Hayward J: Chemotherapy of advanced breast cancer: A controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32:730-736, 1975
10. Carmo-Pereira J, Oliveira Costa F, Henreiques E: Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: A randomized study. Eur J Cancer 16:1621-1625, 1980
11. Steiner R, Stewart JF, Cantwell BJM, et al: Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 19:1553, 1983
12. Andersson M, Daugaard S, von der Maase H, et al: Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: A randomized study. Cancer Treat Rep 70:1181-1186, 1986
13. Gundersen S, Kvinnsland S, Klepp O, et al: Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 22:1431-1434, 1986
14. Ahmann D, Schaid D, Bisel H, et al: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. J Clin Oncol 5:1928-1932, 1987
15. Vaughn C, Green S, O'Bryan R, et al: VP-16 + Adriamycin vs. Adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: A Southwest Oncology Group study. Med Pediatr Oncol 16:312-319, 1988
16. Nielsen D, Dombernowsky P, Skovsgaard T, et al: Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study. Ann Oncol 1:275-280, 1990
17. Group FES: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9:305-312, 1991
18. Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439-3460, 1998
19. Chlebowski R, Irwin L, Pugh R, et al: Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res 39:4503-4506, 1979
20. Smalley R, Murphy S, Huguley CJ, et al: Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 36:3911-3916, 1976
21. Baker L, Vaughn C, Al-Sarraf M, et al: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer. Cancer 33:513-518, 1974